Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

High BMI is a well-known risk factor for the development and recurrence of several solid tumours, including CRC. Obesity is associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab is the main targeted therapy for inhibiting tumour angiogenesis by blocking the VEGF/...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Faruk Aykan, N., Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Keskin, Serkan, Ciftci, Rumeysa, Karabulut, Senem, Sakar, Burak, Disci, Rian
Format: Artigo
Język:Inglês
Wydane: Springer US 2013
Hasła przedmiotowe:
Original Paper
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755215/
https://ncbi.nlm.nih.gov/pubmed/23921648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-013-0679-4
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy